| Bioactivity | Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent[1]. |
| Target | IC50: 25 μM (K+ current) |
| Invitro | Application of 10, 30, 100 and 300 μM Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM)[1]. |
| In Vivo | Sematilide (0.3-1.0 mg/kg, intravenously i.v.) is effective in a canine model of arrhythmia[2]. Animal Model: |
| Name | Sematilide hydrochloride |
| CAS | 101526-62-9 |
| Formula | C14H24ClN3O3S |
| Molar Mass | 349.88 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Ishii Y, et al. Effects of Sematilide, a novel class III antiarrhythmic agent, on membrane currents in rabbit atrial myocytes. Eur J Pharmacol. 1997 Jul 23;331(2-3):295-302. [2]. Stanley S. Greenberg, et al. Pharmacology of Sematilide, a non-quaternary class III antiarrhythmic agent. |